Related Experiment Videos
[Specific immunotherapy using Alpha-Fraction-Retard-D. pteronyssinus. Double-blind study in asthma]
A Sabbah1, F Bonnaud, A Sonneville
1Laboratoire d'Immuno-Allergologie, CHRU, Angers.
Allergie Et Immunologie
|February 1, 1991
Summary
Specific immunotherapy with the Dermatophagoides pteronyssinus alpha-fraction significantly reduced drug consumption in young asthma patients. The treatment demonstrated excellent tolerance and safety in this clinical study.
Area of Science:
- Allergy and immunology
- Pediatric respiratory diseases
- Clinical pharmacology
Background:
- Asthma management often relies on pharmacotherapy.
- Specific immunotherapy (SI) offers a potential disease-modifying approach.
- The efficacy of Dermatophagoides pteronyssinus (Dp) alpha-fraction in pediatric asthma requires further investigation.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of specific immunotherapy using the alpha-fraction of D. pteronyssinus in pediatric asthma patients.
- To assess the impact of this immunotherapy on medication use and overall tolerance.
Main Methods:
- A multicenter, double-blind, randomized controlled trial was conducted.
- Two homogeneous groups (treated with Dp alpha-fraction and untreated) were compared.
- Drug consumption and local/secondary effects were objectively assessed.
Main Results:
- A statistically significant reduction in drug consumption was observed in the treated group, particularly in children under 5 years old (p = 0.047).
- The alpha-fraction immunotherapy was well-tolerated, with excellent local and secondary effects.
- Tolerance profiles were comparable between the treated and untreated groups.
Conclusions:
- Specific immunotherapy with the D. pteronyssinus alpha-fraction is an effective treatment for pediatric asthma.
- This immunotherapy can lead to a significant decrease in medication requirements.
- The treatment is safe and well-tolerated in young children with asthma.